Table 4 Comparison of age at screening, gender, number of co-morbidities and duration of Parkinson’s disease between PTA and TAU groups
n, mean (SD) | GLM analysis | ||||
|---|---|---|---|---|---|
Subgroup variable | Category | PTA | TAU | Difference and 95%CI | p-value |
Age at screening (year) | |||||
≤61 | 33,6.08 (1.49) | 45,5.69 (1.53) | 0.08 (−0.44,0.59) | 0.7752 | |
>61 | 35,6.51 (1.54) | 45,5.79 (1.54) | 0.70 (0.23,1.17) | 0.0036 | |
Gender | |||||
Male | 43,6.33 (1.52) | 52,5.86 (1.49) | 0.29 (−0.17,0.75) | 0.2108 | |
Female | 25,6.24 (1.56) | 38,5.58 (1.58) | 0.51 (−0.03,1.04) | 0.0636 | |
Number of comorbidities | |||||
≤1 | 43,6.13 (1.64) | 59,5.94 (1.45) | 0.21 (−0.18,0.60) | 0.2892 | |
>1 | 25,6.59 (1.26) | 31,5.37 (1.63) | 0.84 (0.15,1.54) | 0.0167 | |
Parkinson’s disease duration (year) | |||||
≤4 | 37,6.56 (1.30) | 52,5.88 (1.55) | 0.47 (−0.03,0.96) | 0.0630 | |
>4 | 31,5.98 (1.71) | 38,5.56 (1.50) | 0.33 (−0.17,0.83) | 0.1917 | |
